Zerit licence restricted

HIV virus
HIV virus

Zerit (stavudine) is now indicated for use in patients with HIV infection only when other antiretrovirals cannot be used and then only for the shortest time possible with a switch to alternative therapy as soon as appropriate.

The SPC for the nucleoside reverse transcriptase inhibitor states that given the severe side effects associated with stavudine therapy, including lactic acidosis, lipoatrophy and polyneuropathy, a benefit-risk assessment should be conducted for each patient and use of an alternative antiretroviral carefully considered.

View Zerit drug record

Further information: Bristol-Myers Squibb

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more